within Pharmacolibrary.Drugs.ATC.C;

model C09DA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.33,
    Cl             = 0.000735,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0343,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.025,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09DA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Losartan and diuretics (typically losartan combined with hydrochlorothiazide) is an antihypertensive combination therapy used in the treatment of high blood pressure. Losartan is an angiotensin II receptor blocker (ARB) while hydrochlorothiazide is a thiazide diuretic; together, they provide a synergistic effect in reducing blood pressure. This combination is approved and widely used in clinical practice for hypertension management.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates are provided for healthy adult subjects after oral administration of losartan in combination with a thiazide diuretic (hydrochlorothiazide). No published studies specifically reporting PK compartmental modeling parameters for the fixed-dose combination product. Estimates based on monograph and available data for the combination.</p><h4>References</h4><ol><li><p>Jeon, I, et al., &amp; Chung, JY (2022). Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan and Chlorthalidone Compared to Concurrent Administration of the Separate Components. <i>Clinical pharmacology in drug development</i> 11(1) 91–99. DOI:<a href=\"https://doi.org/10.1002/cpdd.963\">10.1002/cpdd.963</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34159751/\">https://pubmed.ncbi.nlm.nih.gov/34159751</a></p></li><li><p>Dubey, R, et al., &amp; Muthukrishnan, V (2015). Simultaneous Determination and Pharmacokinetics of Metolazone, Losartan and Losartan Carboxylic Acid in Rat Plasma by HPLC-ESI-MS-MS. <i>Journal of chromatographic science</i> 53(9) 1520–1527. DOI:<a href=\"https://doi.org/10.1093/chromsci/bmv047\">10.1093/chromsci/bmv047</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25947361/\">https://pubmed.ncbi.nlm.nih.gov/25947361</a></p></li><li><p>Sherazi, AW, et al., &amp; Rasool, MF (2024). A Systematic Critical Review of Clinical Pharmacokinetics of Torasemide. <i>Therapeutic drug monitoring</i> 46(3) 309–320. DOI:<a href=\"https://doi.org/10.1097/FTD.0000000000001141\">10.1097/FTD.0000000000001141</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38176856/\">https://pubmed.ncbi.nlm.nih.gov/38176856</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09DA01;
